1 / 53

hematologic and oncologic emergencies

hematologic and oncologic emergencies. wes miller fellow, pediatric hematology and oncology october 31 2007. objectives: AMBITIOUS!. review common presentation, pathophysiogy and (emergent) management of the following the bleeding hemophiliac

huyen
Télécharger la présentation

hematologic and oncologic emergencies

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. hematologic and oncologic emergencies wes miller fellow, pediatric hematology and oncology october 31 2007

  2. objectives: AMBITIOUS! • review common presentation, pathophysiogy and (emergent) management of the following • the bleeding hemophiliac • “the bleeding patient with immune thrombocytopenia purpura (ITP)” • tumor lysis syndrome in the patient with a new malignancy • hyperleukocytosis in acute leukemias or myeloproliferative disease (MPD) • typhlitis • superior vena cava syndrome in the patient with a mediastinal mass

  3. the sickler... • presents a whole new set of emergencies • potential for great morbidity and mortality • more familiar to most ED docs in Atlanta • not addressed here

  4. but, first... • THANKS for the job you do for out patients • we realize our patients are HIGH MAINTENANCE • our attitude on the phone is often one of caution • at risk population • subtleties matter

  5. the bleeding hemophiliac • 8 month old male • presented to PMD with 1 week hx of progressive bilateral LE weakness • diagnosed with GBS, sent to SR ED • at SR ED, noted to have multiple bruises over body (not just over shins), many nodular and hard • history of sublingualfrenular bleed x 10 days following mild trauma in past • history of 2 weeks of oozing at surgical site following neonatal circumcision • history of LP at 6 weeks of life for fever (RSV) • waxing and waning “bulging bruise” at site EVER SINCE

  6. the bleeding hemophiliac • family history negative for bleeding disorders • child with history of vit K ppx at birth, no warfarin or rat poison exposures, no recent antibiotics or diarrhea. • Formula fed; typical baby foods • PE: alert, smiling, clapping. VS wnl. no spontaneous movement of BLE, no withdrawal from painful stimuli, patellar areflexia • CBC normal, platelets robust • PT: 12.6 seconds (normal) • PTT: 125.6 seconds (not normal) • ultrasound: massive thoracolumbosacral paraspinal hematoma

  7. the bleeding hemophiliac

  8. the bleeding hemophiliac • normally, the known hemophiliac will present to your ED • hemophilia • A (“classic”): factor 8 deficiency • B (“christmas disease”): factor 9 deficiency • both coded on X chromosome • disease due to absent or dysfunctionalprotein • clinically INDISTINGUISHABLE • prevalence: 1 in 7500 males • hemophilia A seven times more common than hemophilia B

  9. the bleeding hemophiliac • hemophilia graded according to degree of factor dysfunctionality: • severe: <1% native activity • moderate: 1% - 5% native activity • mild: >5% native activity • where do hemophiliacs bleed? • everywhere!!! • mucocutaneous bleeds (epistaxes, oral, GI) • SOFT TISSUE BLEEDS • HEMARTHROSES!!!!! • muscle bleeds (ileopsoas!) • eyes, renal/GU, throat • CNS !!!!!!!

  10. the bleeding hemophiliac • treatment options • respective recombinant factor replacement(both F8 and F9 deficiency) • DDAVP (mild factor 8 deficiency) • FFP **** (factor 9 deficiency) • cryoprecipitate **** (factor 8 deficiency) • antifibrinolytics (amicar) • treatment strategies • “on demand” • primary prophylaxis • secondary prophylaxis

  11. the bleeding hemophiliac • DOSING SPECIFICS • recombinant factor 8 dosing: • 1 unit/kg of factor 8 raises the activity level 2% • recombinant factor 9 dosing: • 1.5 unit/kg of r-factor 9 raises the acvity level 1% • beware anaphylaxis in F9 replacement • FUNDAMENTAL PRINCIPLE: • when in doubt, treat!!!! • standard rule of thumb: • correct the bleeding hemophiliac child to 80% - 100% activity

  12. the bleeding hemophiliac • barriers to therapy: the dreaded factor inhibitor • 25% - 30% in F8 deficiency • 3% in F9 deficiency • options for patients with inhibitors • FEIBA • do not use antifibrinolytics with FEIBA • recombinant VIIa (novoseven) • antifibrinolytics (amicar)

  13. ITP • 3 y/o male presents with sudden onset, 1 day history full body petechiae and purpura • no epistaxis, melena, hematochezia, hematuria, no h/a, no emesis • no recent fever, no bony pains; excellent energy and appetite • no chronic medications, but mom gave robitussin 2 weeks ago for “cold” • mom frantic: just saw FoxNews special and wants to know if child dying of “meningitis”

  14. ITP • PE: vs wnl • child jumping up and down on exam bed • 8 year old brother then tackles patient who is giggling and about to fall off the bed • head to toe petechia and purpura • OC with multiple purpura, none oozing • CN exam normal, neuro exam normal • no HSM • CBC with differential: • WBC 6k/microL, relative lymphocytosis, 10% atypical lymphocytes, ANC 2000 • hgb 11.8 g/dL • platelets <10k/microL

  15. ITP • the most common AI disorder affecting a hematologic element (1:10,000 kids/year) • peak age: 2 - 6 years • males = females (children) • 2 flavors: • acute (spontaneous resolution < 6 months) • chronic (persistance > 6 months)

  16. ITP • cause: macrophagic destruction of antibody-sensitized platelets • occurs in RES • primary site: spleen • clinical course • usually, antecedent viral illness/vaccination in weeks prior to onset • abrupt onset bleeding/bruising • otherwise HEALTHY kid

  17. ITP • how low do they go?? • plts < 20K: over 80% • usually isolated: expect normal WBC, hgb • anemia in 15% of cases: extracorporeal losses • splenomegaly? • palpable spleen present in 10% • peripheral smear “mandatory” • confirm true t’penia (rule out spurious!) • may see large plts • important negatives: • no WBC abnormalities • no evidence of MAHA • no evidence of AIHA • other work-up: • direct antibody test (DAT/direct Coomb’s) • ABO/Rh blood type

  18. ITP treatment intracranial hemorrhage risk

  19. ITP • where, exactly, do ITP kiddos bleed?? • “most” with petechiae/ecchymoses/purpura • epistaxis/oral wet purpura in < 30% • GI (melena/hematochezia), hematuria in < 10% • menorrhagia in appropriate age group • ICH: 0.1% - 0.9% • how prone to serious bleeding are ITP patients?? • not very!!! • concept of total body platelet mass • bone marrow: LOTS of megakaryocytes! • compare to other thrombocytopenic contexts • iatrogenic post chemo! • risk stratification with absolute platelet count • < 20K/microL: greatest • 20K - 50K/microL: moderate • >50K : insignificant

  20. ITP • reasons to treat: • suspected ICH • known ITP with significant trauma • recurrent or unabating mucosal bleeding • anemia secondary to loss • rarely: extenuating social situation • NOT reasons to treat: • parental anxiety • petechiae or purpura, no matter how florid

  21. ITP • management armamentarium • educate, educate, educate • anticipatory guidance • counsel to avoid antiplatelet meds (ASA, NSAIDs) • Platelets are NOT TYPICALLY HELPFUL**** • observation is commonest strategy • WinRho: monoclonal anti-Rho D antigen antibody • only for non-anemic, DAT negative, Rh+ patients • IVIG • steroids***** • other immunomodulatory agents • splenectomy

  22. ITP • to marrow or not to marrow??? • good concensus: do not marrow if • clinical gestalt consistent with ITP • plan observation alone • plan IVIG and/or anti-D therapy • debatable • plan corticosteroid treatment (even in kids with clinical constellation classic for ITP) • good concensus: marrow if atypical clinical picture • natural history: • resolution in 50% by 4 - 8 weeks • resolution in 65% by 3 months • resolution in 75% by 6 months • 1/3 of “chronic” patients will spontaneously resolve • factors associated with chronicity: • females • age older than 10 (also very young?) • insidious onset

  23. tumor lysis syndrome (TLS) • 8 year old male presents with rapidly distending abdomen, first noticed 4 days ago • febrile, anorexic, pale; stooled yesterday; decreasing UOP • PE: mild distress, large palpable discreet mass in right lower abdomen • CT: large mass near ileocecum • CBC: • WBC 10 K/microL • 3% blasts • mild anemia. • chemistries: • LDH 22,000 U/L (quite high) • uric acid: 12 mg/dL (quite high) • K: 6.1 mmol/L (elevated) • creatinine: 1.3 mg/dL (elevated) • phos: 9 mg/dL (elevated)

  24. TLS high [K+] purines high [phos]

  25. TLS • sudden burden of intravascaular potassium, phosphate and uric acid spilled by dying tumor cells • rhabdomyolysis • crush injuries • thermal injuries (burns/hypothermic exposure) • secondary to massive synchronous release of intracellular contents into extracellular space • typically seen at initiation of therapy for new malignancy, but MAY BE SEEN AT PRESENTATION • consequences: • acute renal failure (urate and CaPhos crystal tubulopathy) • cardiac dysrhythmias • acute hypocalcemia

  26. TLS • identifying patients at risk: • lymphomas: • classically, Burkitt’s lymphoma (practically, any NHL with short doubling time and bulky disease) • leukemias: • especially with high peripheral WBC (>100k/microL) • especially with large extramedullary disease burden: massive HSM, bulky T cell leukemia/lymphoblastic lymphoma • especially with nephromegaly: suggests leukemic renal parenchymal involvement • lymphoproliferative disorders • CML, JMML

  27. TLS • interventions: • hyper-hydration: • beware of oliguria • 2-3 x maintenance of NON POTASSIUM CONTAINING IVF • ?alkalanization • NOT AT CHOA • kayexelate (ideally, oral only), concomitant insulin and glucose, albuterol, CaGluconate**** • renagel • be CAUTIOUS: give supplemental calcium only with EKG changes with hyperkalemia or symptomatic hypocalcemia • goal: keep calcium-phosphate product LOW (<60)

  28. TLS • interventions: • allopurinol • inhibits hypoxanthine oxidase • enzyme critical in metabolic pathway from purine → → →uric acid • rasburicase • urate oxidase • converts uric acid to soluble metabolite (allantoin) • $$$$$ • consult with heme/onc before giving • begin treating malignancy!!!!

  29. hyperleukocytosis • 7 year old male presents to SR ED with CC of decreased energy x 7 days, unresponsive today • exam: • combative, confused, averbal • pupils anisocoric, but responsive • hemiparesis • pallor • tachycardic with gallop • massive HSM • CBC: • WBC: 327K/microL, 94% blasts • hgb: 4.6 g/dL • plts: 16K/microL • DIC panel: • PT: 24 seconds (prolonged) • PTT: 28 seconds (normal) • firbrinogen: 60 (low) • DDimers: 4100 (elevated)

  30. hyperleukocytosis

  31. hyperleukocytosis • patient intubated • surgery emergently consulted to place vas-cath • patient leukapheresed x multiple cycles in PICU • flow cytometry: acute T-cell lymphoblastic leukemia • progressed to renal failure, CVVH • worsening neurologic picture, unilateral fixed pupil • neurosurgery: cranial flap

  32. hyperleukocytosis

  33. hyperleukocytosis • presence of excessive blastemia in the leukemic • defined by peripheral WBC of at least 100K/microL • risk of symptomatology greatly increased for counts of 300K/microL or more • risk of symptomatology greatly increased in AML and CML with increased circulating myeloblasts • seen in • AML: 5%- 20% at presentation • ALL: 9% - 13% at presentation • CML: nearly all patients at presentation

  34. hyperleukocytosis • pathophysiology: • supraphysiologic whole blood viscosity: LEUKOSTASIS • aggregation of blasts in microvasculature • rheologic properties of MYELOBLASTScontribute to worse outcomes in AML or CML • larger than lymphoblasts • less distensible than lymphoblasts • “stickier” than lymphoblasts

  35. hyperleukocytosis • Pathophysiology • inappropriate activation of soluble phase clotting cascade • microvascular occlusion • distal ischemic injury/metabolic acidosis • MAHA (on top of myelophthistic cytopenias) • DIC • reperfusion hemorrhage • MSOF (CNS, pulmonary, renal, hepatic, cardiac, dactylitis, priapism, etc.)

  36. hyperleukocytosis • Interventions   DECREASE WHOLE BLOOD VISCOSITY: • primary intervention: CYTOREDUCTION • leukapheresis • cytoreductive chemotherapy • immediately notify heme/onc • we will urgently activate ARC cytapheresis folks • in the meantime, tip balance to LESS viscosity • immediately begin hyper-hydration (2-3 x maintenance) with non-K+ containing IVF • AVOID PRBC transfusions! • markedly increase whole blood viscosity • if necessary, transfuse with ceiling hgb of 8-9 g/dL • may transfuse platelets liberally if necessary

  37. hyperleukocytosis • interventions: • correct coagulopathy??? • depends! • make plans for urgent placement of vas-cath • manage TLS • who gets leukapheresed? • ANY PATIENT WHO IS SYMPTOMATIC FROM SUSPECTED LEUKOSTASIS SYNDROME • asymptomatic patients: • suspected AML: WBC > 100K/microL • suspected ALL: WBC > 200K/microL • suspected CML: WBC > 200K/microL

  38. typhlitis • 4 year old female • fever to 103, abdominal pain, emesis, bloody diarrhea x one day • undergoing induction chemotherapy for standard risk, B-precursor ALL • finished 2 week steroid course 3 days go • exam: • toxic appearing • tachycardic and hypotensive • mild abdominal distension, hypoactive bowel sounds • guarding on abdominal exam with marked TTP in RLQ • Central capillary refill > 5 seconds • KUB and cross-table lateral: no free air, possible pneumatosis intestinalis noted • CT abdomen: marked cecal bowel wall thickening, peumoatosis intestinalis present

  39. typhlitis • inflammation of the bowel wall, especially at the level of the cecum • seen in children with PROLONGED and PROFOUND neutropenia • Increased risk following chemotherapeutic drugs which cause mucositis • pathogenesis is essentially parallel to neonatal NEC (nectrotizing enterocolitis) • transmural bacterial translocation: PI • risk of bowel perforation • risk of translocated bacteremia: SIRS • pseudomonas aeruginosa • clostridium septicum

  40. typhlitis • at risk patients: • leukemics or NHL patients in induction • may be seen in consolidation for higher intensity regimens • following systemic cytarabine (ARA-C) therapy • especially post high dose cytarabine • any patient with prolonged, profound neutropenia • beware the child “in leukemic induction, coming off steroids, with sudden fever and acute abdomen/signficant RLQ pain”

  41. typhlitis • interventions: • fluid resuscitation • blood culture; stool culture if available • avoid rectal exam • empiric broad spectrum antibiotics (GP, GN, anaerobic coverage) • vancomycin, meropenem +/- aminoglycoside • evaluate for perforation (KUB/CT) • surgery consult if present • inotropic support for hypotension unresponsive to fluid resuscitation

  42. superior vena cava syndrome • 12 year old male, previously healthy • 6 week history of worsening cough • treated 1 week into symptoms with 2 weeks of systemic steroids for “bronchitis” • initially cough improved and felt much better • now worsening • 20 pound weight loss • past week: • worsening orthopnea (sleeping upright in chair) • fevers • past 2 days: • expanding mass in supraclavicular area

  43. SVCS • exam: • alert and non-toxic; completely oriented • facial edema • no stridor, not dyspneic • tachypneic, absent breath sounds R lung • palpable, firm nodes in right supraclavicular chain • splenomegaly

  44. SVCS

  45. SVCS

  46. SVCS • CBC: • WBC: 12K/microL, 13% blasts • hgb: 11.9 g/dL • plts: 144K/microL • quantitative βhCG (tumor marker): normal • quantitative AFP (tumor marker): normal • stat peripheral flow: T cell acute lymphoblastic lymphoma (leukemia?)

  47. SVCS • Interventions: • ICU observation • begun on empiric high dose solumedrol • based upon presence of blasts in smear • next day, begun on induction chemotherapy per flow cytometric diagnosis

  48. SVCS • signs and symptoms from impedence to flow in the SVC • plethora • facial edema • JVD • dyspnea • orthopnea • cough • stridor • for advanced SVC obstruction, may see • confusion • lethargy • headache • vision changes • usually, abnormal SVC flow results from extravascular compression, not a primary intraluminal thrombus

  49. SVCS • causes: mediastinal badness • malignancy • NHL (70% of malignant causes of SVCS) • HL • neuroblastoma • leukemias*** • germ cell tumors • granulomatous disease • aortic aneurysms • primary SVC thrombus

  50. SVCS • accurate diagnosis is critical... • ...however, tissue acquisition can be problematic • do NOT sedate • do NOT give anxiolytics • avoid anything which will compromise • muscular tone • venous return • an already taxed cardiopulmonary state

More Related